Dicycloverine, also known as dicyclomine, is a prescription medication that relieves muscle spasms in the gastrointestinal tract through an apparent mechanism of nonselective smooth muscle relaxation, and that presents a range of anticholinergic side effects. It was first synthesized in the United States around 1945. Dicyclomine is used to treat the symptoms of irritable bowel syndrome, specifically hypermotility, in adults.[1][2] As of 2016, clinical guidelines recommended dicycloverine and other antispasmodics for IBS with diarrhea as a first line treatment, although the evidence for their effectiveness was very weak.[1] This medicine should not be used for people who have an obstructive GI or urinary condition, severe ulcerative colitis, reflux, any unstable cardiac condition, glaucoma, myasthenia gravis, and anyone who is acutely bleeding.[2] It should not be given to children or infants with colic due to the risks of convulsions, difficult breathing, irritability, and restlessness,[3] and there is little evidence to support the efficacy in such use in any case.[4] Because dicycloverine is known to impair thinking and coordination, people taking the drug should avoid driving or operating machinery.[2] The effect on a fetus or on a breastfeeding child is not well understood.[2] Dicycloverine can cause a range of anticholinergic side effects such as dry mouth, nausea, blurred vision, dizziness, confusion, severe constipation, stomach pain, heart palpitations, difficulty urinating, and seizures.[1] Dicycloverine blocks the action of acetylcholine on cholinergic receptors on smooth muscles in the GI tract, relaxing the smooth muscle.[1] Dicycloverine was first synthesized chemically in the United States circa 1945 by scientists at William S. Merrell Company.[5] It was first marketed in 1952 for gastrointestinal disorders, including colic in infants.[3] The INN name "dicycloverine" was recommended in 1959.[6] It was included in the combination drug for morning sickness called Bendectin, along with doxylamine and vitamin B6 which was launched in the US 1956; dicyclomine was removed from the formulation in 1976 after Merrell determined that it added no value. Bendectin became the subject of many lawsuits due to allegations that it had caused birth defects similar to thalidomide, which Merrell had also marketed in the US and Canada.[7] In the mid 1980's several governments restricted its use in infants due to reports of convulsions, difficult breathing, irritability, and restlessness in infants given the drug.[3] In 1994 the US Federal Trade Commission ordered Marion Merrell Dow, which had recently acquired Rugby Darby, the only generic manufacturer of dicycloverine in the US, to promise to grant licenses to its intellectual property on the drug to any company that wanted it, based on antitrust concerns. The US market for the drug at that time was around $8 million; Dow had 60% of it and Rugby had 40%. The next year, Hoechst Marion Roussel, which by that time had acquired the business, granted a license to Endo Pharmaceuticals. By 2000 several other generic competitors had started selling the drug. The case was part of the reshaping of the US pharmaceutical market that occurred in the 1990s, to favor generic entry.[8] There are reports of dicycloverine abuse, but they are rare.[1]